Gurski, Joseph M.

AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas

Elkabets, M., Pazarentzos, E., Juric, D., Sheng, Q., Pelossof, R. A., Brook, S., Benzaken, A. O., Rodon, J., Morse, N., Yan, J. J., et al. (2015) · Cancer Cell

PI3K/AKT/mTOR signaling in cancerLung Cancer Treatments and Mutations

Cited by 325

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF -Mutant Colorectal Cancer through MAPK Pathway Alterations

Ahronian, L. G., Sennott, E. M., Van Allen, E. M., Wagle, N., Kwak, E. L., Faris, J. E., Godfrey, J. T., Nishimura, K., Lynch, K. D., Mermel, C. H., et al. (2015) · Cancer Discovery

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 322

Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours

Corcoran, R. B., Do, K. T., Cleary, J. M., Parikh, A. R., Yeku, O. O., Weekes, C. D., Veneris, J., Ahronian, L. G., Mauri, G., Van Seventer, E. E., et al. (2019) · Annals of Oncology

Melanoma and MAPK PathwaysCell death mechanisms and regulation

Cited by 17